Health
QoL Maintained in Patients With Gynecologic Malignancies Treated on PRIMA Trial – OncLive
Quality of life according to patient-reported outcomes was not reduced despite treatment toxicities in those with ovarian, primary peritoneal, or fallopian tube cancer treated with niraparib versus placebo in the PRIMA/ENGOT-OV26/GOG-3012 trial.
Quality of life (QoL) according to patient-reported outcomes (PROs) was not reduced despite treatment toxicities in those with ovarian, primary peritoneal, or fallopian tube cancer treated with niraparib (Zejula) versus placebo in the PRIMA/ENGOT-OV26/GOG-3012 (NCT02655016) trial, according to a subanalysis presented by Bhavana Pothuri, MD, during the ESMO 2020 Virtual Congress.
PRIMA was an ongoing a randomized, double-blind, placebo-controlled phase 3 trial in which patients with newly diagno…
-
General13 hours agoGymnastics club in Berwick shuts down following child safety complaint
-
Noosa News16 hours agoSanta drops in for carols
-
General18 hours agoCritically endangered orchid thrives as NSW Mid North Coast cemetery provides habitat refuge
-
Business19 hours agoHow to turn small weekly savings into life-changing wealth with ASX shares